dysfunction which is capable of modifying apoptosis dysfunctions said substance being selected from the group consisting of oligosaccharides which are derived, by enzymatic or chemical process, from the polymers of the group comprising (1→3)-β-glucans which optionally comprise (1→6)-β- branching, and oligosaccharides which are derived, by enzymatic or chemical process, from sulfated galactans, it also concerns a method for treating apoptosis dysfunction.

A substitute specification including the claims as filed is herewith enclosed pursuant to 37 CFR 1.125(a).

In the specification, please add the following paragraph after line 17 of page 10, as follows:

Brief Description of the Drawings

Fig. 1 shows a ^{13}C-NMR spectrum of the product referred to as L_{11}.

Fig. 2 shows a histogram showing the results of the first test of example 1.

Fig. 3 shows a histogram showing the results of the second test of example 1.

Fig. 4 shows a histogram showing the results of the third test of example 1 with I_9 concentrations of 0 mg/ml, 0.005 mg/ml, 0.01 mg/ml and 0.05 mg/ml.

Fig. 5 shows a histogram showing the results of the third test of example 1 with I_9 concentrations of 0 mg/ml, 0.1 mg/ml, 0.25 mg/ml and 0.5 mg/ml.

Fig. 6 shows a histogram showing the results of the third test of example 1 with I_9 concentrations of 0 mg/ml, 0.25 mg/ml, 0.5 mg/ml and 1 mg/ml.

Fig. 7 shows a histogram showing the results of the test of example 1 in which the active principle is added 3 hours after FasAb addition.

Fig. 8 shows a histogram showing the results of the test of example 1 in which the active principle is added 6 hours after FasAb addition.

Fig. 9 shows a histogram showing the results of the test of example 1 in which I_9 and staurosporin are added simultaneously.

Figs. 10-13 show a graph illustrating the results of the survival analysis of example 2.

Fig. 14 shows a graph illustrating the stimulation or inhibition of apoptosis caused by 0.2 mg/ml I_9.

Fig. 15 shows a histogram showing the results of the test of example 4.

In the Claims

Please cancel claims 1 to 10 without prejudice and please add new claims 11-28.

11. (New) A medicine comprising as an active principle an effective amount of at least one oligosaccharide substance which is capable of modifying apoptosis dysfunctions, the oligosaccharide substance being selected from the group consisting of oligosaccharides derived by enzymatic or chemical process from polymers of the group consisting of (1→3)-β-glucans, which optionally comprise (1→6)-β- branching, and oligosaccharides derived by enzymatic or chemical process from sulfated galactans.

12. (New) The medicine according to claim 11, wherein the oligosaccharide substance comprises on at least some of its individual units, at least one substituent of the group consisting of sulfate, methyl and acetyl groups.

13. (New) The medicine according to claim 11, wherein the oligosaccharides are derived from carrageenans, agars or porphyrans.